Bisphosphonates for pain management in children with benign cartilage tumors.

Abstract

OBJECTIVES:

Cochrane meta-analyses have shown significant benefit in bone pain from bisphosphonate therapy in adults with bone diseases such as multiple myeloma, Paget disease, breast and prostate cancer. Our aim was to assess if bisphosphonate treatment could alleviate severe pain in children with Ollier disease and hereditary multiple exostoses that are refractory to standard analgesics.

METHODS:

We report our clinical experience with bisphosphonate therapy in 2 children with cartilage tumors, one with Ollier disease, and the other with hereditary multiple exostoses.

RESULTS:

We found bisphosphonate therapy to be helpful for pain relief and improving overall ability to carry out daily activities.

DISCUSSION:

One can consider bisphosphonate therapy in children with Ollier disease and hereditary multiple exostoses who have debilitating pain that is refractory to standard analgesic treatment.

• Authors: Mark J Winston, Tarak Srivastava, Dale Jarka, Uri S Alon
• Journal: The Clinical journal of pain (Clin J Pain) 2012 Mar-Apr Vol. 28 Issue 3 Pg. 268-72 ISSN: 1536-5409 [Electronic] United States
• PMID: 21904199 (Publication Type: Case Reports, Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Bone Density Conservation Agents
• Diphosphonates

Topics

• Bone Density Conservation Agents (therapeutic use)
• Bone Neoplasms (complications)
• Cartilage (pathology)
• Child
• Diphosphonates (therapeutic use)
• Female
• Humans
• Male
• Pain (drug therapy, etiology)
• Pain Measurement